Sugi Predict

Sugi Predict / Compounds / SCHEMBL35861

SCHEMBL35861

SCHEMBL35861

COC(=O)c1ccc(OC)c(C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.64
▸ KMT2A Q03164 2/20 0.57
▸ TAS1R3 Q7RTX0 5/20 0.55
▸ TAS1R1 Q7RTX1 5/20 0.55
▸ ALDH1A1 P00352 4/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ MGLL Q99685 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ CA1 P00915 2/20 0.53
▸ CA2 P00918 2/20 0.53
▸ CA12 O43570 1/20 0.53
▸ CA7 P43166 1/20 0.53
▸ XDH P47989 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ CA14 Q9ULX7 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ ALOX15 P16050 1/20 0.51
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14499505 0.86 ERN1 (0.54) MAPTKMT2ATAS1R3TAS1R1ALDH1A1
SCHEMBL1757167 0.85 MAPT (0.64) MAPTKMT2ATAS1R3TAS1R1ALDH1A1
SCHEMBL31721306 0.85 MAPT (0.64) MAPTKMT2ATAS1R3TAS1R1ALDH1A1
SCHEMBL11577171 0.84 CYP1A2 (0.70) MAPTTAS1R3TAS1R1ALDH1A1CYP2C9
Veratric Acid Methyl Ester SCHEMBL2050732 0.84 MAPT (0.86) MAPTKMT2AALDH1A1CYP2C9MGLL
Veratric Acid Methyl Ester SCHEMBL29573244 0.84 MAPT (0.86) MAPTKMT2AALDH1A1CYP2C9MGLL
SCHEMBL1899654 0.84 MAPT (0.50) MAPTKMT2ATAS1R3TAS1R1ALDH1A1
SCHEMBL5866557 0.84 HSD17B2 (0.69) MAPTKMT2ATAS1R3TAS1R1ALDH1A1
SCHEMBL1458956 0.84 MAPT (0.50) MAPTKMT2ATAS1R3TAS1R1ALDH1A1
SCHEMBL701782 0.82 CA12 (0.71) TAS1R3TAS1R1ALDH1A1CYP2C9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250073236-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS APROS THERAPEUTICS INC (US) 2025-03-06 — — US disclosed
WO-2024199069-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 — — WO disclosed
CN-118724916-A Polyaryl-containing macrocyclic compounds and uses thereof 浙江养生堂天然药物研究所有限公司 2024-10-01 — — CN disclosed
WO-2023218195-A1 GCN2 INHIBITORR IP2IPO INNOVATIONS LIMITED (GB) 2023-11-16 — — WO disclosed
CN-111253404-B Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2023-05-23 — — CN disclosed
CN-110177780-B Pyrimidine compounds containing acidic groups 阿普罗斯治疗公司 2022-11-01 — — CN disclosed
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-02-17 — — US disclosed
WO-2021250399-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2021-12-16 — — WO disclosed
EP-3548478-B1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS APROS THERAPEUTICS INC (US) 2021-11-17 — — EP disclosed
US-11173157-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators Apros Therapeutics, Inc. (US) 2021-11-16 — — US disclosed
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 — — US disclosed
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 — — US disclosed
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
WO-2007067478-A2 P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2007-06-14 — — WO disclosed
US-20070129372-A1 P38 kinase inhibiting agents MERCK SHARP & DOHME CORP. 2007-06-07 — — US disclosed
EP-1728792-A1 8-OXOADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-06 — — EP disclosed
WO-1997003967-A1 SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE RHONE-POULENC RORER LIMITED (GB) 1997-02-06 — — WO disclosed
US-4444567-A ALKOXY BENZALDEHYDES, ALKOXY BENZOATES PHILLIPS PETROLEUM COMPANY (US) 1984-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS MAPT 2288/4885KMT2A 1891/4885TAS1R3 2992/4885
US-20070225303-A1 8-Oxoadenine Compound TLR7, CCR8, TLR8 MAPT 4054/4885KMT2A 825/4885TAS1R3 2370/4885
US-20250073236-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS MAVS, TLR7, STING1 MAPT 4286/4885KMT2A 2768/4885TAS1R3 1507/4885
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof MAPK11, WEE1, NOS1 MAPT 4194/4885KMT2A 3961/4885TAS1R3 4830/4885
US-11173157-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators TLR7, TLR9, MAVS MAPT 4464/4885KMT2A 2064/4885TAS1R3 1396/4885
US-20070129372-A1 P38 kinase inhibiting agents MAPK1, MAPK8, MAPK7 MAPT 79/4885KMT2A 4540/4885TAS1R3 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.